Henry Joseph Breslin

USPTO Granted Patents = 37 (Patent Applications = 1)

CIPO Patents = 6

EPO Patents = 14 (Patent Applications = 13)

Average Co-Inventor Count = 4.2

ph-index = 10

Forward Citations = 198(Granted Patents)

Location History:

Lansdale, NJ (US) (2006 - 2012)
Lansdale, PA (US) (1993 - 2019)

Company Filing History:

23 out of 2,076

Janssen Pharmaceutica Nv

Atrin Pharmaceuticals LLC

Cancer Research Technology Limited

patents

6. 1 out of 832,680

Other

patents

Years Active: 1993-2019

Loading Chart...

37 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10301324 - Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use (2019-05-28),

2. 10213415 - Compounds as opioid receptor modulators (2019-02-26),

3. 10196405 - Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors (2019-02-05),

4. 9981989 - Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors (2018-05-29),

5. 9914730 - Azaquinazoline inhibitors of Atypical protein Kinase C (2018-03-13),

6. 9896446 - Azaquinazoline inhibitors of atypical protein kinase C (2018-02-20),

7. 9700542 - Compounds as opioid receptor modulators (2017-07-11),

8. 9663535 - Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors (2017-05-30),

9. 9487529 - Macrocyclic compounds as ALK, FAK and JAK2 inhibitors (2016-11-08),

10. 9238656 - Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders (2016-01-19),

11. 9205076 - Compounds as opioid receptor modulators (2015-12-08),

12. 8895573 - Phenoxy-substituted pyrimidines as opioid receptor modulators (2014-11-25),

13. 8772325 - Compounds as opioid receptor modulators (2014-07-08),

14. 8609709 - Compounds as opioid receptor modulators (2013-12-17),

15. 8552186 - Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors (2013-10-08),

Title: Henry Joseph Breslin: Pioneering Innovator Shaping the Future

Introduction:

Henry Joseph Breslin, a visionary inventor based in Lansdale, PA, is renowned for his passion for innovation and dedication to pushing the boundaries of what is possible. With 37 patents to his name, his work continues to inspire future generations of inventors to dream big and create solutions that shape the world we live in.

Latest Patents:

Henry Joseph Breslin's latest patents include groundbreaking inventions such as Ataxia Telangiectasia and Rad3-Related (ATR) inhibitors and methods of their use. These compounds and compositions inhibit ATR Protein Kinase, showcasing his commitment to developing cutting-edge solutions in the field of pharmaceuticals. Additionally, his work on novel opioid receptor modulators further demonstrates his ability to innovate and address complex medical needs.

Career Highlights:

Having worked with esteemed companies like Janssen Pharmaceutica NV and Cephalon, Inc., Henry Joseph Breslin has made significant contributions to the pharmaceutical industry. His dedication to research and development has led to the creation of pioneering solutions that have the potential to revolutionize healthcare and improve patient outcomes.

Collaborations:

Throughout his career, Henry Joseph Breslin has collaborated with talented individuals such as Wei He and Robert William Kavash. Together, they have worked on innovative projects that have pushed the boundaries of what is possible in the world of inventions and patents. Their passion for innovation and commitment to excellence have set a high standard for the industry.

Conclusion:

In conclusion, Henry Joseph Breslin's remarkable career as a pioneering innovator underscores his unwavering commitment to excellence and passion for pushing the boundaries of what is possible. His groundbreaking inventions and collaborations serve as a testament to his enduring legacy in the world of inventions, inspiring future generations to continue pushing the frontiers of innovation.

This text is generated by artificial intelligence and may not be accurate.